Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid

J Dermatol. 2023 Feb;50(2):e76-e78. doi: 10.1111/1346-8138.16559. Epub 2022 Aug 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Pemphigoid, Bullous* / complications
  • Pemphigoid, Bullous* / diagnosis
  • Pemphigoid, Bullous* / drug therapy
  • Psoriasis* / complications
  • Psoriasis* / diagnosis
  • Psoriasis* / drug therapy

Substances

  • ixekizumab
  • Antibodies, Monoclonal, Humanized